GlassScriptPhysician profile
Aakashi D Patel
NPI 1184069973
$2,969.06
in general payments reported to CMS, 2019-2025
21 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $658 · 2022: $322 · 2023: $204 · 2024: $731 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $980.20 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $570.98 | 2021-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $501.00 | 2021-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $163.61 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $98.77 | 2021-2025 | Tremfya, Stelara |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.18 | 2025 | Lifevest |
| Madrigal Pharmaceuticals | $84.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $79.01 | 2024-2025 | Omvoh |
| Vivus LLC | $59.37 | 2021-2025 | Pancreaze |
| Ardelyx, INC. | $42.06 | 2024 | Ibsrela |
| Qol Medical, LLC | $38.62 | 2024 | Sucraid |
| Fresenius Kabi USA, LLC | $37.27 | 2023-2024 | Idacio |
| Genzyme Corporation | $35.98 | 2024 | |
| Organon LLC | $35.62 | 2024-2025 | Renflexis, Hadlima |
| Gilead Sciences, INC. | $32.62 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $29.45 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $21.69 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.63 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $19.80 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $15.83 | 2022 | |
| Recordati_rare_diseases_inc. | $14.90 | 2025 | Panhematin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aakashi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.